Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CDTTW
Upturn stock ratingUpturn stock rating

Conduit Pharmaceuticals Inc. (CDTTW)

Upturn stock ratingUpturn stock rating
$0.01
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CDTTW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.01
high$

Analysis of Past Performance

Type Stock
Historic Profit -64.29%
Avg. Invested days 6
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 2
52 Weeks Range 0.01 - 0.05
Updated Date 05/21/2025
52 Weeks Range 0.01 - 0.05
Updated Date 05/21/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -168.26%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 552357
Shares Outstanding -
Shares Floating 552357
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Conduit Pharmaceuticals Inc.

stock logo

Company Overview

overview logo History and Background

Conduit Pharmaceuticals Inc. (CDT) was founded in 2020 as a special purpose acquisition company (SPAC) and subsequently acquired and merged with a late-stage biopharmaceutical company. The aim is to develop new treatments for unmet medical needs.

business area logo Core Business Areas

  • Human therapeutics: Conduit is focussed on late-stage small molecule therapeutics including inflammatory disease, infectious disease, and other human ailments.

leadership logo Leadership and Structure

Details regarding Conduit Pharmaceuticals' leadership team and organizational structure can be found on the company's investor relations webpage. Focus is on bringing late stage assets to market.

Top Products and Market Share

overview logo Key Offerings

  • AZD1656 (exenatide extended release): A once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes. Competitors include Novo Nordisk (NVO) and Eli Lilly (LLY) with their respective GLP-1 receptor agonists. Market share data is pending market entrance.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by high research and development costs, long regulatory approval processes, and intense competition. Innovation is key, and companies must adapt to evolving healthcare needs and regulatory landscapes.

Positioning

Conduit Pharmaceuticals is positioned as a late-stage development company focused on bringing assets to market. Its competitive advantage hinges on efficient development and commercialization.

Total Addressable Market (TAM)

The TAM for diabetes and other inflammatory diseases is estimated to be several billion dollars. CDT is positioned to address a portion of this TAM with its late-stage asset.

Upturn SWOT Analysis

Strengths

  • Late-stage product pipeline
  • Experienced management team
  • Focus on unmet medical needs

Weaknesses

  • Limited commercial infrastructure
  • Dependence on successful clinical trials
  • Limited revenue

Opportunities

  • Expanding into new therapeutic areas
  • Partnerships and collaborations
  • Market entry for lead products

Threats

  • Regulatory hurdles
  • Competition from established players
  • Clinical trial failures
  • Patent Expiry

Competitors and Market Share

competitor logo Key Competitors

  • NVO
  • LLY
  • SNY
  • MRK

Competitive Landscape

Conduit Pharmaceuticals faces significant competition from established pharmaceutical companies with greater resources and commercial infrastructure. CDT's advantages lie in its late-stage assets and focused development strategy.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is not applicable given the company's recent formation and developmental stage.

Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and market acceptance of its products. Analyst projections should be referred to.

Recent Initiatives: Recent strategic initiatives involve clinical trial progression and regulatory submissions.

Summary

Conduit Pharmaceuticals is a developmental-stage company focusing on late-stage assets in areas of unmet medical need. It possesses a high-risk, high-reward profile and lacks significant commercial operations. Its success hinges on successful clinical trials, regulatory approvals, and partnerships and market entry. Key watch-outs are the competition from large pharmaceutical firms and potential regulatory hurdles and reliance on capital markets.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Financial news sources
  • Industry reports

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data is estimated and subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Conduit Pharmaceuticals Inc.

Exchange NASDAQ
Headquaters Naples, FL, United States
IPO Launch date 2023-09-25
Founder, CEO & Director Dr. Andrew Regan
Sector Healthcare
Industry Biotechnology
Full time employees 6
Full time employees 6

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.